BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 35587601)

  • 21. Multiple endocrine neoplasia type 2B mutation in human RET oncogene induces medullary thyroid carcinoma in transgenic mice.
    Acton DS; Velthuyzen D; Lips CJ; Höppener JW
    Oncogene; 2000 Jun; 19(27):3121-5. PubMed ID: 10871866
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of genetically modified T-cell receptors that recognize the CEA:691-699 peptide in the context of HLA-A2.1 on human colorectal cancer cells.
    Parkhurst MR; Joo J; Riley JP; Yu Z; Li Y; Robbins PF; Rosenberg SA
    Clin Cancer Res; 2009 Jan; 15(1):169-80. PubMed ID: 19118044
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A transplantable human medullary thyroid carcinoma as a model for RET tyrosine kinase-driven tumorigenesis.
    Johanson V; Ahlman H; Bernhardt P; Jansson S; Kölby L; Persson F; Stenman G; Swärd C; Wängberg B; Stridsberg M; Nilsson O
    Endocr Relat Cancer; 2007 Jun; 14(2):433-44. PubMed ID: 17639056
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma.
    Fox E; Widemann BC; Chuk MK; Marcus L; Aikin A; Whitcomb PO; Merino MJ; Lodish M; Dombi E; Steinberg SM; Wells SA; Balis FM
    Clin Cancer Res; 2013 Aug; 19(15):4239-48. PubMed ID: 23766359
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multiple endocrine neoplasia type 2B with a RET proto-oncogene A883F mutation displays a more indolent form of medullary thyroid carcinoma compared with a RET M918T mutation.
    Jasim S; Ying AK; Waguespack SG; Rich TA; Grubbs EG; Jimenez C; Hu MI; Cote G; Habra MA
    Thyroid; 2011 Feb; 21(2):189-92. PubMed ID: 21186952
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low prevalence of the somatic M918T RET mutation in micro-medullary thyroid cancer.
    Romei C; Ugolini C; Cosci B; Torregrossa L; Vivaldi A; Ciampi R; Tacito A; Basolo F; Materazzi G; Miccoli P; Vitti P; Pinchera A; Elisei R
    Thyroid; 2012 May; 22(5):476-81. PubMed ID: 22404432
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genetic analysis of a hereditary medullary thyroid carcinoma case with normal preoperative serum calcitonin levels.
    Zhang G; Jiang Y; Zhang S; Zhao L; Fan J; Zhang Z; Ma J; Chen R; Xu Y
    Pathol Res Pract; 2019 Oct; 215(10):152529. PubMed ID: 31409511
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of medullary thyroid carcinoma in transgenic mice expressing the RET protooncogene altered by a multiple endocrine neoplasia type 2A mutation.
    Michiels FM; Chappuis S; Caillou B; Pasini A; Talbot M; Monier R; Lenoir GM; Feunteun J; Billaud M
    Proc Natl Acad Sci U S A; 1997 Apr; 94(7):3330-5. PubMed ID: 9096393
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Classical point mutations of RET, BRAF and RAS oncogenes are not shared in papillary and medullary thyroid cancer occurring simultaneously in the same gland.
    Ciampi R; Romei C; Pieruzzi L; Tacito A; Molinaro E; Agate L; Bottici V; Casella F; Ugolini C; Materazzi G; Basolo F; Elisei R
    J Endocrinol Invest; 2017 Jan; 40(1):55-62. PubMed ID: 27535135
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CGH alterations in medullary thyroid carcinomas in relation to the RET M918T mutation and clinical outcome.
    Frisk T; Zedenius J; Lundberg J; Wallin G; Kytölä S; Larsson C
    Int J Oncol; 2001 Jun; 18(6):1219-25. PubMed ID: 11351254
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-carcinoembryonic antigen antibodies versus somatostatin analogs in the detection of metastatic medullary thyroid carcinoma: are carcinoembryonic antigen and somatostatin receptor expression prognostic factors?
    Behr TM; Gratz S; Markus PM; Dunn RM; Hüfner M; Schauer A; Fischer M; Munz DL; Becker H; Becker W
    Cancer; 1997 Dec; 80(12 Suppl):2436-57. PubMed ID: 9406695
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Case Report of Sequential Use of a Yeast-CEA Therapeutic Cancer Vaccine and Anti-PD-L1 Inhibitor in Metastatic Medullary Thyroid Cancer.
    Del Rivero J; Donahue RN; Marté JL; Gramza AW; Bilusic M; Rauckhorst M; Cordes L; Merino MJ; Dahut WL; Schlom J; Gulley JL; Madan RA
    Front Endocrinol (Lausanne); 2020; 11():490. PubMed ID: 32849281
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Retroposed copies of RET gene: a somatically acquired event in medullary thyroid carcinoma.
    Bim LV; Navarro FCP; Valente FOF; Lima-Junior JV; Delcelo R; Dias-da-Silva MR; Maciel RMB; Galante PAF; Cerutti JM
    BMC Med Genomics; 2019 Jul; 12(1):104. PubMed ID: 31288802
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Medullary Thyroid Carcinoma Associated with Germline RET
    Xu JY; Grubbs EG; Waguespack SG; Jimenez C; Gagel RF; Sosa JA; Sellin RV; Dadu R; Hu MI; Trotter CS; Jackson M; Rich TA; Hyde SM; Sherman SI; Cote GJ
    Thyroid; 2016 Dec; 26(12):1744-1751. PubMed ID: 27673361
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence and clinical spectrum of nonsecretory medullary thyroid carcinoma in a series of 839 patients with sporadic medullary thyroid carcinoma.
    Frank-Raue K; Machens A; Leidig-Bruckner G; Rondot S; Haag C; Schulze E; Lorenz A; Kreissl MC; Dralle H; Raue F; Schmid KW
    Thyroid; 2013 Mar; 23(3):294-300. PubMed ID: 22946486
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Measurement of calcitonin and calcitonin gene-related peptide mRNA refines the management of patients with medullary thyroid cancer and may replace calcitonin-stimulation tests.
    Camacho CP; Lindsey SC; Melo MC; Yang JH; Germano-Neto F; Valente Fde O; Lima TR; Biscolla RP; Vieira JG; Cerutti JM; Dias-da-Silva MR; Maciel RM
    Thyroid; 2013 Mar; 23(3):308-16. PubMed ID: 23259706
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Medullary Thyroid Cancer - Feature Review and Update on Systemic Treatment.
    Dabelić N; Jukić T; Fröbe A
    Acta Clin Croat; 2020 Jun; 59(Suppl 1):50-59. PubMed ID: 34219884
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of the Genomic Profile of Medullary Thyroid Carcinoma with Tumor Characteristics and Clinical Outcomes in an International Multicenter Study.
    Xu B; Viswanathan K; Ahadi MS; Ahmadi S; Alzumaili B; Bani MA; Baudin E; Behrman DB; Capelletti M; Chau NG; Chiarucci F; Chou A; Clifton-Bligh R; Coluccelli S; de Biase D; De Leo A; Dogan S; Fagin JA; Fuchs TL; Glover AR; Hadoux J; Lacroix L; Lamartina L; Lubin DJ; Luxford C; Magliocca K; Maloberti T; Mohanty AS; Najdawi F; Nigam A; Papachristos AJ; Repaci A; Robinson B; Scoazec JY; Shi Q; Sidhu S; Solaroli E; Sywak M; Tuttle RM; Untch B; Barletta JA; Al Ghuzlan A; Gill AJ; Ghossein R; Tallini G; Ganly I
    Thyroid; 2024 Feb; 34(2):167-176. PubMed ID: 37842841
    [No Abstract]   [Full Text] [Related]  

  • 39. MiR-182 promotes cancer invasion by linking RET oncogene activated NF-κB to loss of the HES1/Notch1 regulatory circuit.
    Spitschak A; Meier C; Kowtharapu B; Engelmann D; Pützer BM
    Mol Cancer; 2017 Jan; 16(1):24. PubMed ID: 28122586
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preoperative diagnosis of medullary thyroid carcinoma by RT-PCR using RNA extracted from leftover cells within a needle used for fine needle aspiration biopsy.
    Takano T; Miyauchi A; Matsuzuka F; Liu G; Higashiyama T; Yokozawa T; Kuma K; Amino N
    J Clin Endocrinol Metab; 1999 Mar; 84(3):951-5. PubMed ID: 10084577
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.